SIC
GMAB icon

SJS Investment Consulting’s Genmab GMAB Stock Holding History

SJS Investment Consulting’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54
Closed -$1.66K – 2519
2025
Q4 		$1.66K Buy
+54
New +$1.68K ﹤0.01% 1173
2022
Q1 		$12K Hold
342
– – ﹤0.01% 367
2021
Q4 		$14K Buy
+342
New +$14.3K ﹤0.01% 324

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SJS Investment Consulting's GMAB Position: Q1 2026 in Review

SJS Investment Consulting sold out of Genmab (GMAB) in Q1 2026, closing a stake of 54 shares — an estimated $1.66K sold.

SJS Investment Consulting first reported a position in GMAB in Q4 2021 and held it in 3 quarters. The position peaked at $14K in Q4 2021. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • SJS Investment Consulting reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 54 Genmab shares in Q1 2026, an estimated $1.66K.
  • SJS Investment Consulting first reported a position in Genmab in Q4 2021 and held it in 3 quarters.
  • SJS Investment Consulting's Genmab position peaked at $14K in Q4 2021.
  • 274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.